Pimecrolimus Cream 1% plus topical corticosteroid in patients with severe atopic dermatitis

Journal of Drugs in Dermatology, Nov-Dec, 2005

This study is currently recruiting patients. Sponsored by Novartis. Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation), and pruritus (skin itching). The active ingredient of pimecrolimus inhibits the T-cell activation. These cells are involved in the inflammatory component of the disease. This study will test the safety of pimecrolimus Cream 1% with topical corticosteroid treatment (commonly used in eczema) in patients with severe atopic dermatitis.

Condition           Intervention           Phase

Dermatitis, Atopic  Pimecrolimus cream 1%  Phase IV

Study ID Numbers: ASM981C2439

ClinicalTrials.gov Identifier: NCT00121381

COPYRIGHT 2005 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here

Content provided in partnership with Thompson Gale